Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines (CabACC)
Multicenter, Prospective, Non-randomized, Phase II Trial Designed to Evaluate the Activity of Cabazitaxel in Patients With Advanced Adreno-Cortical- Carcinoma Progressing After Previous Chemotherapy Lines
Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Listed as NCT03257891, this PHASE2 trial focuses on Adrenocortical Carcinoma and remains ongoing. Sponsored by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, it has been updated 8 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Recruiting PHASE2
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — May 2020 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2017 — May 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
- San Luigi Gonzaga Hospital
For direct contact, visit the study record on ClinicalTrials.gov .